Project 2 of the Johns Hopkins Alzheimer's Disease Research Center (ADRC) is titled """"""""Modeling an anti-amyloid therapy for AD: potential for cognitive recovery"""""""". This project focuses the role of oligomeric amyloid-beta (A-beta) peptides in the cognitive impairment associated with Alzheimer's disease (AD). The project will test the hypothesis that accumulation of oligomeric A-beta species impairs learning and memory and that these cognitive impairments can be reversed with suppression of A-beta generation. To address this question we will use a mouse model of A-beta amyloidosis in which the expression of mutant amyloid precursor protein (APP) is controlled by a tetracycline-regulated promoter (these transgenic mice are known as TetOffAPP mice). A-beta production can be suppressed in these mice with doxycycline. Preliminary data suggest that following A-beta suppression with doxycycline, amyloid deposits are stable but there is, nevertheless, a gradual amelioration of the memory deficits. This finding has led to the following three specific aims: (1) Aim 1: To determine whether the reduction of oligomoeric A-beta species derived from newly-synthesized A-beta peptides improves learning and memory in the conditional TetOffAPP mouse models after genetically induced arrest of APP expression and new A-beta production. (2) Aim 2: To determine whether recovery of synaptic damage is associated with cognitive improvement after A-beta production - synaptic, glutamatergic and immediate early gene markers of neuronal activity will be assessed in mice with significant amelioration of memory deficits. (3) Aim 3: To examine the role of neurodegenerative changes in CNS monoamine systems in relation to the degree of cognitive recovery observed after reduction of A-beta peptides in the TetOffAPP mice. Collectively, outcomes from these studies will address an important issue regarding the value of an anti-amyloid therapeutic strategy for AD by assessing the magnitude of functional repair and recovery after synaptic damage by oligomeric A-beta. Evaluation of outcomes of therapeutic interventions that target A-beta production will inform appropriate expectations in clinical trials.
Understanding mechanisms that influence the pathology of Alzheimer's disease, and whether it is possible to reduce pathology once it has developed, is of crucial importance in developing strategies to combat Alzheimer's disease, a neurodegenerative disorder which affects over 6 million Americans.
|Hibar, Derrek P (see original citation for additional authors) (2017) Novel genetic loci associated with hippocampal volume. Nat Commun 8:13624|
|Haberman, Rebecca P; Koh, Ming Teng; Gallagher, Michela (2017) Heightened cortical excitability in aged rodents with memory impairment. Neurobiol Aging 54:144-151|
|Jeong, Yun Ha; Ling, Jonathan P; Lin, Sophie Z et al. (2017) Tdp-43 cryptic exons are highly variable between cell types. Mol Neurodegener 12:13|
|Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2017) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord :|
|Rawlings, Andreea M; Sharrett, A Richey; Mosley, Thomas H et al. (2017) Glucose Peaks and the Risk of Dementia and 20-Year Cognitive Decline. Diabetes Care 40:879-886|
|Mori, Susumu; Kageyama, Yusuke; Hou, Zhipeng et al. (2017) Elucidation of White Matter Tracts of the Human Amygdala by Detailed Comparison between High-Resolution Postmortem Magnetic Resonance Imaging and Histology. Front Neuroanat 11:16|
|Valera, Elvira; Spencer, Brian; Mott, Jennifer et al. (2017) MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy. Front Mol Neurosci 10:329|
|Brenowitz, Willa D; Keene, C Dirk; Hawes, Stephen E et al. (2017) Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging 53:83-92|
|Gross, Alden L; Hassenstab, Jason J; Johnson, Sterling C et al. (2017) A classification algorithm for predicting progression from normal cognition to mild cognitive impairment across five cohorts: The preclinical AD consortium. Alzheimers Dement (Amst) 8:147-155|
|Liu, Peiying; Li, Yang; Pinho, Marco et al. (2017) Cerebrovascular reactivity mapping without gas challenges. Neuroimage 146:320-326|
Showing the most recent 10 out of 713 publications